Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Beontag – CCRR Group (”Beontag”) in connection with the acquisition of Scandstick AB with subsidiaries and Linerless AB (the “Scandstick Group”)
Mandate

Vinge advises Beontag – CCRR Group (”Beontag”) in connection with the acquisition of Scandstick AB with subsidiaries and Linerless AB (the “Scandstick Group”)

February 10, 2022 M&A Employment and Benefits

Vinge advises Beontag in connection with the acquisition of the Scandstick Group. Scandstick is an international group in the self adhesive industry with head office in Höganäs, Sweden. The Scandstick Group has approximately 150 employees and production facilities in Sweden, Slovenia, Poland and Belgium.

Beontag is the largest manufacturer in Latin America of RAIN RFID inlays and tags.

Vinge’s team consisted of Magnus Pauli, Sofie Nordgren (Project Manager), Johanna Hamrefält (M&A manager), Tilda Hall (Commercial and Real Estate) Agaton Lindgren (Finance) and Anna Ståhlklo (Employment), among others.

Selih & Partnerji in Slovenia, Wardynski & Partners in Poland and Liedekerke in Belgium acted as local counsels in connection with the transaction.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025